APO Research
Talk to an analyst

APO RESEARCH · REPORT

Group A and C Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Group A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2026

27 December 2025121 pages

Choose your research edition.

Industry ResearchGroup A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Group A and C Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Group A and C Meningococcal Polysaccharide Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Group A and C Meningococcal Polysaccharide Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Group A and C Meningococcal Polysaccharide Vaccine include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Group A and C Meningococcal Polysaccharide Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Group A and C Meningococcal Polysaccharide Vaccine Market by Company

Pfizer

Sanofi Pasteur

AIM Bio

Chengda Biotechnology

GlaxoSmithKline

Cansino Biologics

Sinovac

Lanzhou Institute of Biological Products

Royal (Wuxi) Bio-Pharmaceutical

Merck & Co.

Toyouvax

Walvax

Zhifei Biological

Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine

Polysaccharide Vaccine

Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Group A and C Meningococcal Polysaccharide Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Group A and C Meningococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Group A and C Meningococcal Polysaccharide Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Group A and C Meningococcal Polysaccharide Vaccine Sales (Units) of Manufacturers (2021-2026) Table 7. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Group A and C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Group A and C Meningococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Product Type & Application Table 14. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Group A and C Meningococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Pfizer Company Information Table 19. Pfizer Business Overview Table 20. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 22. Pfizer Recent Developments Table 23. Sanofi Pasteur Company Information Table 24. Sanofi Pasteur Business Overview Table 25. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 27. Sanofi Pasteur Recent Developments Table 28. AIM Bio Company Information Table 29. AIM Bio Business Overview Table 30. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 32. AIM Bio Recent Developments Table 33. Chengda Biotechnology Company Information Table 34. Chengda Biotechnology Business Overview Table 35. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 37. Chengda Biotechnology Recent Developments Table 38. GlaxoSmithKline Company Information Table 39. GlaxoSmithKline Business Overview Table 40. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 42. GlaxoSmithKline Recent Developments Table 43. Cansino Biologics Company Information Table 44. Cansino Biologics Business Overview Table 45. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 47. Cansino Biologics Recent Developments Table 48. Sinovac Company Information Table 49. Sinovac Business Overview Table 50. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 52. Sinovac Recent Developments Table 53. Lanzhou Institute of Biological Products Company Information Table 54. Lanzhou Institute of Biological Products Business Overview Table 55. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 57. Lanzhou Institute of Biological Products Recent Developments Table 58. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 59. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 60. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 62. Royal (Wuxi) Bio-Pharmaceutical Recent Developments Table 63. Merck & Co. Company Information Table 64. Merck & Co. Business Overview Table 65. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 67. Merck & Co. Recent Developments Table 68. Toyouvax Company Information Table 69. Toyouvax Business Overview Table 70. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 72. Toyouvax Recent Developments Table 73. Walvax Company Information Table 74. Walvax Business Overview Table 75. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 77. Walvax Recent Developments Table 78. Zhifei Biological Company Information Table 79. Zhifei Biological Business Overview Table 80. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 82. Zhifei Biological Recent Developments Table 83. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (Units) Table 85. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 86. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (Units) Table 87. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 88. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 90. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 92. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 94. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 95. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 99. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 100. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 104. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 105. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 109. South America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 110. South America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 114. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 115. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 118. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 119. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 120. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 121. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 124. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 125. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2026) & (US$/Unit) Table 126. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2027-2032) & (US$/Unit) Table 127. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 128. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 129. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 130. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 131. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 134. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 135. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2026) & (US$/Unit) Table 136. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Group A and C Meningococcal Polysaccharide Vaccine Distributors List Table 140. Group A and C Meningococcal Polysaccharide Vaccine Customers List Table 141. Group A and C Meningococcal Polysaccharide Vaccine Industry Trends Table 142. Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers Table 143. Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Group A and C Meningococcal Polysaccharide Vaccine Product Image Figure 5. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (Units) Figure 8. Global Group A and C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Polysaccharide-protein Conjugate Vaccine Product Image Figure 10. Polysaccharide Vaccine Product Image Figure 11. Hospital Product Image Figure 12. Centers for Disease Control and Prevention Product Image Figure 13. Others Product Image Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Group A and C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region in 2025 Figure 20. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region in 2025 Figure 21. North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 22. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 23. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 24. United States Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 28. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 29. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 30. Germany Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 41. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 43. China Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 52. South America Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 53. South America Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 54. Brazil Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 58. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 60. Egypt Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 66. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 67. Global Group A and C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Type (2021-2032) Figure 68. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 69. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 70. Global Group A and C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Application (2021-2032) Figure 71. Group A and C Meningococcal Polysaccharide Vaccine Value Chain Figure 72. Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Polysaccharide-protein Conjugate Vaccine
  • Polysaccharide Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Chengda Biotechnology
  • GlaxoSmithKline
  • Cansino Biologics
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck & Co.
  • Toyouvax
  • Walvax
  • Zhifei Biological

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2021-2032)
  5. 2.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (2021-2032)
  6. 2.3 Group A and C Meningococcal Polysaccharide Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Polysaccharide-protein Conjugate Vaccine
  9. 2.3.3 Polysaccharide Vaccine
  10. 2.4 Group A and C Meningococcal Polysaccharide Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Centers for Disease Control and Prevention
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales (Units) of Manufacturers (2021-2026)
  3. 3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Group A and C Meningococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Established Date
  9. 3.9 Global Group A and C Meningococcal Polysaccharide Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Pfizer
  2. 4.1.1 Pfizer Company Information
  3. 4.1.2 Pfizer Business Overview
  4. 4.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 4.1.5 Pfizer Recent Developments
  7. 4.2 Sanofi Pasteur
  8. 4.2.1 Sanofi Pasteur Company Information
  9. 4.2.2 Sanofi Pasteur Business Overview
  10. 4.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 4.2.5 Sanofi Pasteur Recent Developments
  13. 4.3 AIM Bio
  14. 4.3.1 AIM Bio Company Information
  15. 4.3.2 AIM Bio Business Overview
  16. 4.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 4.3.5 AIM Bio Recent Developments
  19. 4.4 Chengda Biotechnology
  20. 4.4.1 Chengda Biotechnology Company Information
  21. 4.4.2 Chengda Biotechnology Business Overview
  22. 4.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 4.4.5 Chengda Biotechnology Recent Developments
  25. 4.5 GlaxoSmithKline
  26. 4.5.1 GlaxoSmithKline Company Information
  27. 4.5.2 GlaxoSmithKline Business Overview
  28. 4.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 4.5.5 GlaxoSmithKline Recent Developments
  31. 4.6 Cansino Biologics
  32. 4.6.1 Cansino Biologics Company Information
  33. 4.6.2 Cansino Biologics Business Overview
  34. 4.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 4.6.5 Cansino Biologics Recent Developments
  37. 4.7 Sinovac
  38. 4.7.1 Sinovac Company Information
  39. 4.7.2 Sinovac Business Overview
  40. 4.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 4.7.5 Sinovac Recent Developments
  43. 4.8 Lanzhou Institute of Biological Products
  44. 4.8.1 Lanzhou Institute of Biological Products Company Information
  45. 4.8.2 Lanzhou Institute of Biological Products Business Overview
  46. 4.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 4.8.5 Lanzhou Institute of Biological Products Recent Developments
  49. 4.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 4.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 4.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 4.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 4.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 4.10 Merck & Co.
  56. 4.10.1 Merck & Co. Company Information
  57. 4.10.2 Merck & Co. Business Overview
  58. 4.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 4.10.5 Merck & Co. Recent Developments
  61. 4.11 Toyouvax
  62. 4.11.1 Toyouvax Company Information
  63. 4.11.2 Toyouvax Business Overview
  64. 4.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  66. 4.11.5 Toyouvax Recent Developments
  67. 4.12 Walvax
  68. 4.12.1 Walvax Company Information
  69. 4.12.2 Walvax Business Overview
  70. 4.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  72. 4.12.5 Walvax Recent Developments
  73. 4.13 Zhifei Biological
  74. 4.13.1 Zhifei Biological Company Information
  75. 4.13.2 Zhifei Biological Business Overview
  76. 4.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  78. 4.13.5 Zhifei Biological Recent Developments
5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Scenario by Region
  1. 5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  16. 5.5.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  18. 5.5.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  41. 5.7.1 South America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  43. 5.7.3 South America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (Units)
  3. 6.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (Units)
  3. 7.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 8.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process
  5. 8.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
  8. 8.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
9 Global Group A and C Meningococcal Polysaccharide Vaccine Analyzing Market Dynamics
  1. 9.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
  2. 9.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 9.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 9.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst